Clinical Trial Results with Novel Agents and Regimens for the Treatment of Newly Diagnosed or Relapsed/Refractory AML/MDS, Including in the Elderly


Clinical Trial Results with Novel Agents and Regimens for the Treatment of Newly Diagnosed or Relapsed/Refractory AML/MDS, Including in the Elderly
Slides from presentations at ASCO 2011 and comments from Susan M O’Brien, MD

Faderl S et al. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. Proc ASCO 2011;Abstract 6503.

Dr O'Brien is Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.